NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,407.81 +200.68 (+1.10%) CRUDE OIL
79.16 +0.21 (+0.27%) GOLD FUTURES
2,310.60 +1.00 (+0.04%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,730.79 +2,134.54 (+4.68%)
Annovis Bio, Inc. (ANVS)
After hours:
| Previous close | 6.11 |
| Open | 6.20 |
| Bid | 5.53 x 3200 |
| Ask | 5.58 x 800 |
| Day's range | 5.45 - 6.20 |
| 52-week range | 5.23 - 22.49 |
| Volume | |
| Avg. volume | 437,868 |
| Market cap | 60.067M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.25 |
ZacksZoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
ZacksNovo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
- Reuters
UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as 60%. The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer's disease (AD) along two scales assessing cognition and cognitive dysfunction. In a press release, the company said a "post-hoc" analysis of the trial data had shown statistically significant results in improving cognition function scores along an Alzheimer's disease scale in a subgroup of patients who had mild disease and who tested positive for certain disease biomarkers.
